Effects of Otago and Frenkel's Exercises on Strengthening of Antigravity Muscles in Parkinson's Disease.

November 29, 2025 updated by: University of Lahore
Using both Otago and Frenkel's exercises offers complementary benefits building muscle strength and refining coordination in anti-gravity muscles making daily activities safer and more fluid for people with Parkinson's.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Combining Otago and Frenkel's exercises can slow functional decline, reduce falls, and improve quality of life for Parkinson's patients. These programs empower patients and families by promoting active participation in care rather than relying only on medications. Early introduction, guided by physiotherapists, gives the best outcomes helping patients stay mobile, confident, and independent for longer.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
40

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Pakistan
    • Punjab Province
      • Gujranwala, Punjab Province, Pakistan, 50250
        • University of Lahore

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. Patient diagnosed with parkinsons disease using the Hoehn and Yahr scale
  2. Patient age 55-75.
  3. Both male and female.
  4. Able to walk independently.
  5. Willing and ability to provide information consent to participate in study. -

Exclusion Criteria:

  1. Presence of other neurological condition(stroke, multiple sclerosis).
  2. severe cardiovascular disease.
  3. major psychiatric disorder.
  4. currently participating in other study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Otago Exercise Program
20 Participants in this arm will undergo a combined exercise program consisting of the Otago Exercise Program (OEP) and conventional Physiotherapy. The intervention is designed to strengthen antigravity muscles (hip, knee, and trunk extensors), improve balance, coordination, and functional mobility, and reduce fall risk in patients with Parkinson's disease.
Behavioral: Otago exercises
After collecting the patient's data appropriate modalities will be applied to initiate the treatment session. This includes the use of an Electric Heating pad on the lower limb for 10 mints. Gentle walking will be performed for 1 mints along with arm swing (10 repetitions) and neck stretching focusing on upper trapezius muscle (3 repetition).After that the12 steps of Otago exercise will be performed with 10 repetition.Total session time is 40 mints.
Experimental: Frenkel's Exercise Program
20 Participants in this arm will under go Frenkel's Exercises program and conventional physiotherapy. This intervention help Parkinsons patient by improving coordination, balance and enhance motor learning and confidence
Behavioral: Frenkels exercise
After collecting the patient's data sessions will be delivered 3 times per week lasting for 40 mints only and than appropriate modalities will be applied to initiate the treatment session. This includes the use of an Electric Heating pad on the lower limb for 10 mints. Gentle walking will be performed for 1 mints along with arm swing (10 repetitions) and neck stretching focusing on upper trapezius muscle (3 repetition).After that the steps of Frenkels exercise program will be performed on patients with 10 repetition.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Antigravity muscle strenght (Manual Muscle strength).
Time Frame: Baseline before treatment (week 0) post -interventiom (week 4 )

Strength of major antigravity muscle including Hip muscles, Knee muscles and ankle muscles.

strength evaluated by using Manual Muscle Testing based on oxford Grading Scale (0-5).

. Grade 0 ( No contraction).

  • Grade 1 (trace): slightly contraction detected but no movement occur at joint.
  • Grade 2 (poor): Full range of motion in a gravity eliminated position.
  • Grade 3(Fair): Full range of motion against gravity.
  • Grade4 (Good): Full range of motion against gravity moderate resistance.
  • Grade5 (Normal) Full Range of motion against gravity and maximum resistance. Participants tested in standardized position for each group. unit of measurement : MMT grade (0-5)
Baseline before treatment (week 0) post -interventiom (week 4 )
Balance and reduction in fall risk.
Time Frame: baseline Before treatment (0 Week) post- intervention ( 4 week )
Balance assessed through the Berg Balance Scale (BBS). Berg Balance Scale items: 14 Tasks (sit to stand, standing, stepping, unsupported, reaching, turning) total score (0-56) scoring:0-4 for each task Maximum score=56 41-56=low Fall risk 21-40=Medium Fall risk 0-20=High Fall risk
baseline Before treatment (0 Week) post- intervention ( 4 week )

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
University of Lahore

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
August 18, 2025

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
August 18, 2025

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
August 18, 2025

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
August 26, 2025

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
November 29, 2025

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
December 11, 2025

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
December 11, 2025

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
November 29, 2025

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
August 1, 2025

More Information

Terms related to this study

Keywords

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • UOL/IREB/25/09/0051
  • UOL (UOL/IREB/25/09/0051)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings